Evidence map›Paper›PMID 19332817›Full record

ArticleMicrobiology (Reading, England)2009

Single-copy chromosomal integration systems for Francisella tularensis.

Eric D LoVullo, Claudia R Molins-Schneekloth, Herbert P Schweizer, Martin S Pavelka

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Microbiology (Reading, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. FEMS microbes · 2026
    Article
  3. Tolfenpyrad displaysMicrobiology spectrum · 2023
    Article
  4. Article
  5. Article
  6. Intracellular Experimental Evolution ofACS infectious diseases · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Glycoconjugate vaccine using a genetically modified O antigen induces protective antibodies toProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Contributions of TolC Orthologs toInfection and immunity · 2019
    Article
  13. Emerging microbes & infections · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Construction of a New Phage Integration Vector pFIV-Val for Use in DifferentFrontiers in cellular and infection microbiology · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eric D LoVulloDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Claudia R Molins-SchneeklothDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Herbert P SchweizerDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Martin S PavelkaDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Colorado State University · USUniversity of Rochester Medical Center · US

Funding

Vascular stabilization as a broad theraprutic platform for biodefenseU54AI065357 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI BLAIR, CAROL D · 2005 to 2013
$77.5M
Training in Microbial PathogenesisT32AI007362 · NIAID · UNIVERSITY OF ROCHESTER · PI IGLEWSKI, BARBARA H. · 1990 to 2010
$2.6M
Identification of secreted proteins important for tulremia pathogenesisR21AI068013 · NIAID · UNIVERSITY OF ROCHESTER · PI PAVELKA, MARTIN S. · 2006 to 2007
$384k
Genetic Tools for Pathogenic BacteriaR03AI058141 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI SCHWEIZER, HERBERT P. · 2004 to 2005
$145k
NIAID NIH HHS AI058141NIAID NIH HHS AI065357NIAID NIH HHS AI068013NIAID NIH HHS R03 AI058141NIAID NIH HHS R21 AI068013NIAID NIH HHS T32 AI007362NIAID NIH HHS T32 AI007362-18NIAID NIH HHS U54 AI065357
6 · The paper itself

Abstract

Francisella tularensis is a fastidious Gram-negative bacterium responsible for the zoonotic disease tularemia. Investigation of the biology and molecular pathogenesis of F. tularensis has been limited by the difficulties in manipulating such a highly pathogenic organism and by a lack of genetic tools. However, recent advances have substantially improved the ability of researchers to genetically manipulate this organism. To expand the molecular toolbox we have developed two systems to stably integrate genetic elements in single-copy into the F. tularensis genome. The first system is based upon the ability of transposon Tn7 to insert in both a site- and orientation-specific manner at high frequency into the attTn7 site located downstream of the highly conserved glmS gene. The second system consists of a sacB-based suicide plasmid used for allelic exchange of unmarked elements with the blaB gene, encoding a beta-lactamase, resulting in the replacement of blaB with the element and the loss of ampicillin resistance. To test these new tools we used them to complement a novel d-glutamate auxotroph of F. tularensis LVS, created using an improved sacB-based allelic exchange plasmid. These new systems will be helpful for the genetic manipulation of F. tularensis in studies of tularemia biology, especially where the use of multi-copy plasmids or antibiotic markers may not be suitable.

Indexed as

DNA Transposable ElementsMutagenesis, InsertionalRecombination, GeneticAllelesAnti-Bacterial AgentsBacterial ProteinsChromosomes, BacterialConjugation, GeneticDNA, BacterialFrancisella tularensisGenetic TechniquesGenetic VectorsHumansPenicillinsPlasmidsAnti-Bacterial AgentsBacterial ProteinsDNA, BacterialDNA Transposable ElementsPenicillins

Identifiers

PMID19332817
PMCPMC2895234
OpenAlexW2170135581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.